SignalXSignalX

LQDA Liquidia Corp

Q3 2025 10-Q
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Liquidia Corp Overview

Liquidia Corp (LQDA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New legal risk: United Therapeutics lawsuits seeking injunction to remove YUTREPIA from PAH/PH-ILD markets, risking loss of FDA approval or sales suspension
  • • Most material update: Accumulated deficit $640.9M as of Sep 30, 2025, net losses $83.5M (9 months 2025) versus $128.3M (2024) and $78.5M (2023), ongoing loss uncertainty
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$54M

Net Income

-$4M

Operating Margin

3.3%

Net Margin

-6.5%

ROE

-16.0%

Total Assets

$276M

Source: XBRL data from Liquidia Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Liquidia Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.